Structural and Functional Microcirculatory Aspects of Patients with (suspected) Connective Tissue Disease and Pulmonary Arterial Hypertension

Structural and Functional Microcirculatory Aspects of Patients with (suspected) Connective Tissue Disease and Pulmonary Arterial Hypertension - Microcirculation in CTD and PAH

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON30520

Enrollment

300

Registered

2007-01-26

Start date

2006-12-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

elevated pressure in the main blood vessel of the lung Pulmonary arterial hypertension

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Age 18-80 -Healthy -Raynaud's phenomenon -connective tissue disease (with or without pulmonary hypertension) -Pulmonary hypertension (primary, familial, secondary to CTD)

Exclusion criteria

Exclusion criteria: -age 80 years -for healthy controls: smoking, skin disease affecting the fingers/nails, diabetes mellitus, hypertension, symptoms/signs/past medical history of connective tissue disease or pulmonary disease

Design outcomes

Primary

Measure	Time frame
a) Prevalence and severity of structural and functional derangements in the microcirculation in patients with UCTD complicated by PAH compared with patients with UCTD but without PAH b) Correlation of the degree and type of structural abnormalities of the microcirculation and severity of endothelial dysfunction with the phenotype of PAH c) Effect of vasoactive agents that influence vascular function used in the treatment of PAH such as prostanoids, endothelin-1 antagonists, and PDE-5 inhibitors on microcirculatory structure and function in patients with PAH and its correlation with clinical effectivity.	—

Measure

Time frame

a) Prevalence and severity of structural and functional derangements in the microcirculation in patients with UCTD complicated by PAH compared with patients with UCTD but without PAH b) Correlation of the degree and type of structural abnormalities of the microcirculation and severity of endothelial dysfunction with the phenotype of PAH c) Effect of vasoactive agents that influence vascular function used in the treatment of PAH such as prostanoids, endothelin-1 antagonists, and PDE-5 inhibitors on microcirculatory structure and function in patients with PAH and its correlation with clinical effectivity.

—

Countries

Netherlands

Outcome results